Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Nanomix Corp
NNMX
Healthcare
Medical Devices
Nanomix Corporation is engaged in development of mobile point-of-care diagnostics. The Company operates through its Nanomix eLab System platform and assays that provide quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The platform is designed to provide rapid test results in a handheld device at the first point of patient...
contact in locations that range from emergency departments to long term and assisted care facilities, to urgent care and emergency medical response settings. Its platform is performed in a range of in vitro diagnostic assays, such as electrochemical immunoassay and enzymatic assays. Its eLab System utilizes a nano-biosensor with multiple detection electrodes to generate multiple electrochemical assay results. Its S1 Assay panel is used as an aid in diagnosing infections, such as sepsis. Its CRP test results can be used to evaluate infection, tissue injury, and inflammatory disorders.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (GREY:NNMX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Jan 27, 2014 5:39pm
Boston Therapeutics, Inc. (BTHE) Addressing the Diabetes Epi
Boston Therapeutics, Inc. (BTHE) Addressing the Diabetes Epidemic with Promising Drug Candidates Approximately 25.8 million Americans have diabetes, according to the National Diabetes Education
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Jan 21, 2014 6:39pm
Boston Therapeutics, Inc. (BTHE) Prepares for Third Phase Tr
Boston Therapeutics, Inc. (BTHE) Prepares for Third Phase Trial of PAZ320 Boston Therapeutics is a pharmaceutical company focused on the development, manufacturing, and commercialization of novel
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Jan 13, 2014 6:12pm
Boston Therapeutics, Inc. (BTHE) Heads into 2014 with Strong
Boston Therapeutics, Inc. (BTHE) Heads into 2014 with Strong, Experienced Leadership Boston Therapeutics is developing a pipeline of novel compounds to address unmet medical needs in diabetes. The
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Jan 06, 2014 5:59pm
Boston Therapeutics, Inc. (BTHE) Tackles One of America’s Gr
Boston Therapeutics, Inc. (BTHE) Tackles One of America’s Greatest Epidemics It’s turning out to be one of the biggest epidemic waves in American history, with estimated costs nationally jumping
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Dec 27, 2013 7:22pm
Pivotal Phase 3 Trial a Key Objective for Boston Therapeutic
Pivotal Phase 3 Trial a Key Objective for Boston Therapeutics (BTHE) in 2014 Boston Therapeutics is a pharmaceutical company using complex carbohydrate chemistry to advance its PAZ320 and IPOXYN drug
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Dec 17, 2013 5:47pm
Boston Therapeutics, Inc. (BTHE) is Creating a Better Drug t
Boston Therapeutics, Inc. (BTHE) is Creating a Better Drug to Prevent and Treat Diabetes In the United States alone, an estimated 26 million people have Type 2 diabetes while another 80 million or so
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Dec 10, 2013 5:30pm
Boston Therapeutics, Inc. (BTHE) Announces Three Management
Boston Therapeutics, Inc. (BTHE) Announces Three Management Appointments Boston Therapeutics, an innovator of drugs that target diabetes using complex carbohydrate chemistry, today announced the
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Dec 09, 2013 7:53pm
Boston Therapeutics, Inc. (BTHE) Takes Firm Stance Against T
Boston Therapeutics, Inc. (BTHE) Takes Firm Stance Against Type 2 Diabetes, Backed by High-Potential Candidate Pipeline Boston Therapeutics is developing a pipeline of therapeutic molecules based on
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Dec 09, 2013 7:45pm
Boston Therapeutics, Inc. (BTHE) Receives Positive Highlight
Boston Therapeutics, Inc. (BTHE) Receives Positive Highlight at Seeking Alpha In an article published recently on Seeking Alpha, Boston Therapeutics was highlighted as a biopharmaceutical company with
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Nov 25, 2013 6:34pm
Boston Therapeutics, Inc. (BTHE) on Accelerated Path for Dru
Boston Therapeutics, Inc. (BTHE) on Accelerated Path for Drug Development Boston Therapeutics is a pharmaceutical company focused on the development and commercialization of novel compounds based on
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Nov 18, 2013 5:44pm
Boston Therapeutics, Inc. (BTHE) Presenting at Elsevier Ther
Boston Therapeutics, Inc. (BTHE) Presenting at Elsevier Therapeutic Area Partnerships 2013 Conference Boston Therapeutics, a company focusing on the development of diabetes treatments using complex
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Nov 14, 2013 3:53pm
Boston Therapeutics, Inc. (BTHE) Exhibiting PAZ320 at Inaugu
Boston Therapeutics, Inc. (BTHE) Exhibiting PAZ320 at Inaugural Obesity Week 2013 Conference Boston Therapeutics, a company focusing on the development of drugs using complex carbohydrate chemistry to
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Nov 12, 2013 3:53pm
Boston Therapeutics, Inc. (BTHE) Begins Enrolling Patients i
Boston Therapeutics, Inc. (BTHE) Begins Enrolling Patients in Phase 2b Trial for PAZ320 Boston Therapeutics announced it has begun enrolling patients in a Phase 2b Trial for its PAZ320 drug today. A
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Nov 05, 2013 6:10pm
Boston Therapeutics, Inc. (BTHE) – Could the Move Away from
Boston Therapeutics, Inc. (BTHE) – Could the Move Away from Fats be Contributing to Obesity? Although the idea of low-fat diets has a long history, it really took off in the 1980s when major American
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Nov 05, 2013 2:01pm
16-Page Investor Relations Kit is Now Available Online
16-Page Investor Relations Kit is Now Available Onlinehttps://bthe.missionir.com/ir Please read full disclaimers at https://disclaimer.missionir.com
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Xcyte Digital Corp. Releases "Xperience" Subscription Service
Drilling Approval Received for New Mexico Lithium Project
GameSquare Announces Formation of FaZe Media, Backed by $11M Investment